Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1198 of 6351
-
A simple taste test could revolutionize depression treatment
Diagnosis PausedThe study looks at whether a taste test device can be used as a diagnostic aid for depression. Taste tests will be carried out before and after first use of an antidepressant (prescribed by the patient's GP) and then again six to eight weeks later a further taste test will be con…
Sponsor: Ranvier Health Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New DNA test could revolutionize diagnosis of eye infections
Diagnosis CompletedThis is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New Huntington's drug shows promise in Mid-Stage trial
Disease control CompletedThe primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a diabetes drug boost heart function in non-diabetic patients?
Symptom relief OngoingThe proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or pla…
Phase 3 • Sponsor: National Institute of Cardiology, Warsaw, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control CompletedThis is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Phase 1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New osteoporosis drug could offer cheaper alternative to prolia
Disease control CompletedThis is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis
Phase 3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:15 UTC
-
Hydrogel implant could offer reversible male contraception
Disease control CompletedThis study will evaluate the safety and feasibility of the ADAM System for implantation into the vas deferens in 25 healthy males at 3 sites. This is a prospective, non-randomized, open label interventional trial.
Sponsor: Contraline, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New heart device aims to prevent strokes in patients with a hole in the heart
Disease control OngoingThe objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/pro…
Sponsor: Occlutech International AB • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a common supplement ease lupus?
Disease control OngoingSystemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the dep…
Phase 2 • Sponsor: State University of New York - Upstate Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer clot study halted: new drug vs standard care
Disease control Stopped earlyThis is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Phase 3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill could protect hearts in rare genetic disease
Disease control OngoingThis is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventri…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
A gel injection may erase 'tech neck' lines, and a trial puts it to the test
Symptom relief CompletedThe cumulative effects of aging, weight change, ergonomics (i.e., "tech neck"), and environmental exposures (i.e., ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles, discoloration, laxity, and roughness of sun exposed skin. The neck is a frequent…
Phase 3 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New imaging agent could sharpen pancreatic cancer detection
Diagnosis CompletedThis is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of \[68Ga\]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The \[68Ga\]FAPI-46 PET scans will be acquired after initial stag…
Phase 2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New SPECT scans could spot aggressive breast cancer without biopsy
Diagnosis CompletedAn open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where the primary endpoint of the study is to compare imaging properties of 99mTc-ADAPT6 and 99mTc-D…
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Can couples counseling curb HIV? new study tests dyadic approach in south africa
Prevention CompletedFrom a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control…
Sponsor: University of Michigan • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
Real-Time text messages from your fitness tracker: a new way to fight diabetes?
Disease control CompletedSedentary behaviour has a detrimental effect on the mortality, morbidity, and well-being of patients with type 2 diabetes and prediabetes, and general practitioners should advise patients on how to self-monitor and increase their physical activity. The emergence of mobile health …
Sponsor: Charles University, Czech Republic • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Own stem cells may shield bone marrow during ovarian cancer chemo
Disease control Recruiting nowThe aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protec…
Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Weekly combo shot shows promise for better blood sugar control
Disease control CompletedThis study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Smart lung pressure strategy tested in 676 ICU patients
Disease control CompletedThis study is a multicentric randomized controlled study.The objective of this study is to compare the prognosis of patients with ARDS between EIT-oriented individualized PEEP and traditional lower PEEP/FiO2 table-oriented PEEP strategy.
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cholesterol shot shows promise in large trial
Disease control CompletedStudy of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC